Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.48) Estimate
Portfolio Pulse from bharat@benzinga.com
Atea Pharmaceuticals reported Q3 losses of $(0.40) per share, beating the analyst consensus estimate of $(0.48) by 16.67%. However, this represents a 300% increase in losses compared to the same period last year.
November 08, 2023 | 10:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Atea Pharmaceuticals' Q3 losses were less than expected but significantly higher than last year. This mixed result could lead to uncertainty in the market.
Atea Pharmaceuticals' Q3 results were better than expected, which could have a positive impact on the stock. However, the significant increase in losses compared to last year could negatively affect investor sentiment, leading to potential volatility in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100